not exactly the same but an interesting article it shows how intense this sector is right now http://www.fiercebiotech.com/story/...-defector-headed-rival-astrazeneca/2015-06-01
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%